{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.37","upperLimit":"78.77","value":"64.77"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"The Kaplan-Meier method will be used to estimate 3-year OS, defined as the time from study entry until death.","dispersionType":"95% Confidence Interval","groups":[{"description":"IND I: Pts receive cytarabine IT \\& ADE as in Arm A, IND I \\& sorafenib tosylate PO at the time of known HR FLT3/ITD+ (including IND I \\& concurrently with chemo).\n\nIND II: Pts receive cytarabine IT day (d) 1, cytarabine IV over 1-30 minutes on d 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours d 1-5, sorafenib tosylate PO d 9-36.\n\nINTE I: Pts receive cytarabine IT and AE in Arm A, INT II, and sorafenib tosylate PO on daily d 6-28.\n\nINT II: Pts receive cytarabine IT on d 1, MA as in Arm A, IND II (HR pts), sorafenib tosylate PO d 7-34.\n\nSCT (HR patients with matched family \\[MFD\\] or unrelated donor):\n\nPts receive fludarabine phosphate IV over 30 minutes once daily on d -5 to -2, busulfan IV over 2 hours 4 times daily d -5 to -2.\n\nPts undergo allogeneic SCT within 36-48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting d 40-100 after INT II or SCT for 1 year.","id":"OG000","title":"Arm C (Cohort 2)"}],"paramType":"NUMBER","populationDescription":"Patients ineligible, did not start treatment, or on Arm D are excluded from analyses of OS. Arm D patients who were not eligible for Arm C by the end of induction I were declared off study per protocol; thus, no outcome data were collected for Arm D patients.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"OS for Patients on Arm C, Cohort 2","type":"SECONDARY","unitOfMeasure":"percentage of patients"}